Items where authors include "Ashcroft, AJ"

Article

Snowden, JA, Ahmedzai, SH, Cox, A et al. (10 more authors) (2022) Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study. Bone Marrow Transplantation, 57 (10). pp. 1507-1513. ISSN 0268-3369

Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Pratt, G et al. (13 more authors) (2020) Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy. British Journal of Haematology. ISSN 0007-1048

Ahmedzai, SH, Snowden, JA, Ashcroft, AJ et al. (19 more authors) (2019) Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. Journal of Clinical Oncology, 37 (19). pp. 1617-1628. ISSN 0732-183X

Cook, G, Royle, K-L, O'Connor, S et al. (20 more authors) (2019) The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. British Journal of Haematology, 185 (3). pp. 450-467. ISSN 0007-1048

Striha, A orcid.org/0000-0003-3363-8417, Ashcroft, AJ, Hockaday, A et al. (12 more authors) (2018) The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial. Trials, 19. 169. p. 169. ISSN 1745-6215

Cook, G orcid.org/0000-0003-0223-3652, Ashcroft, AJ, Cairns, DA orcid.org/0000-0002-2338-0179 et al. (16 more authors) (2016) The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial. The Lancet Haematology, 3 (7). e340-e351.